Retatrutide

Retatrutide is an experimental "triple agonist" peptide that represents the latest frontier in metabolic and incretin research. Unlike previous generations of peptides, Retatrutide targets three distinct hormone receptors simultaneously: GLP-1 (Glucagon-like peptide-1), GIP (Glucose-dependent insulinotropic polypeptide), and GCGR (Glucagon receptor).

Research Applications

Retatrutide is being studied for its strong effects on energy balance and body weight. It activates GLP-1 and GIP receptors to boost insulin and reduce appetite, while GCGR antagonism increases energy use and targets liver fat. This triple-action approach shows promise for obesity, Type 2 Diabetes, and NAFLD. Early data indicates Retatrutide may have better weight management results than dual-agonists like Tirzepatide.

Product Specifications

• Mechanism: Triple Agonist (GLP-1R / GIPR / GCGR)

• Purity: ≥99% (HPLC verified)

• Format: Lyophilised powder

Storage & Stability Protocols

• Lyophilised Powder: Stable at room temperature for 3 weeks; store at -20°C for up to 48 months.

• Reconstituted Solution: Store at 2–8°C, stable for 21–30 days.

• Protection: Keep vials away from light, heat and moisture. 

COA available on request

Note: This product is sold strictly for laboratory research and analytical purposes only. It is not intended for human or animal consumption or medical use.